The amputation concern with SGLT2 inhibitors came from the CANVAS trial, where canagliflozin users had more toe and foot amputations. Later empagliflozin and dapagliflozin trials did not show the same signal, and the US FDA removed canagliflozin's boxed warning in 2020. Anyone with an active ulcer, severe artery disease or dehydration should review them.
SGLT2 inhibitors amputation risk became a concern after the CANVAS trial found more lower-limb amputations among patients taking canagliflozin. Later studies of empagliflozin and dapagliflozin did not establish the same increased risk. The US FDA removed canagliflozin's boxed warning in 2020, but foot monitoring remains important, especially for patients with active ulcers, poor circulation or previous amputations.
Key Takeaways
-
SGLT2 inhibitors are diabetes medicines that lower blood glucose by increasing glucose excretion through urine.
-
The CANVAS Program reported approximately twice the risk of lower-limb amputation with canagliflozin compared with placebo.
-
The increased risk was mainly observed in toe and midfoot amputations.
-
Large trials of empagliflozin and dapagliflozin did not establish the same amputation signal.
-
The FDA removed canagliflozin's boxed warning in August 2020, but the risk remains described in its prescribing information.
-
SGLT2 inhibitors provide important heart and kidney benefits for many patients.
-
Patients with active foot ulcers, peripheral artery disease or previous amputation need individual risk assessment.
-
Do not stop prescribed diabetes medication without consulting the treating physician, except when following an established sick-day or emergency medical plan.
What Are SGLT2 Inhibitors?
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are prescription medicines used in the management of type 2 diabetes and certain heart and kidney conditions.
They work mainly by blocking glucose reabsorption in the kidneys.
As a result, excess glucose is passed out through urine, helping reduce blood sugar levels.
Common SGLT2 inhibitors include:
-
Canagliflozin
-
Empagliflozin
-
Dapagliflozin
-
Ertugliflozin
These medicines may also provide cardiovascular and kidney benefits in appropriately selected patients.
However, patients with diabetic foot complications sometimes worry about their possible effect on circulation, ulcers and amputation risk.
Understanding the evidence is important because different medicines have not shown identical findings in clinical trials.
Where Did the SGLT2 Amputation Warning Come From?
The concern about SGLT2 inhibitors amputation risk originated mainly from the CANVAS Program.
CANVAS evaluated cardiovascular outcomes in patients with type 2 diabetes who were at increased cardiovascular risk.
The study compared canagliflozin with placebo.
What Did the CANVAS Trial Find?
The CANVAS Program reported approximately 6.3 lower-limb amputations per 1,000 patient-years among participants taking canagliflozin, compared with 3.4 per 1,000 patient-years in the placebo group.
This represented an approximately twofold relative increase.
Most amputations involved toes or the midfoot, although more extensive amputations also occurred.
The finding was important because patients with diabetes may already have increased risk of:
-
Peripheral artery disease
-
Diabetic neuropathy
-
Foot ulcers
-
Poor wound healing
-
Previous foot infection
-
Lower-limb amputation
Why Was Canagliflozin Linked to Amputation?
The exact mechanism behind the CANVAS amputation signal remains uncertain.
Researchers considered several possible explanations, including volume depletion and the interaction of treatment with existing vascular or foot disease.
However, a definitive causal mechanism was not established.
Patients with previous amputation, peripheral vascular disease or neuropathy were at higher baseline risk.
This does not prove that canagliflozin directly caused every amputation observed during the trial.
What Did the FDA Do?
In 2017, the US Food and Drug Administration added a boxed warning about lower-limb amputation risk to canagliflozin-containing medicines.
In August 2020, the FDA removed the boxed warning after reviewing additional evidence and considering the medicine's demonstrated cardiovascular and kidney benefits.
However, the amputation risk was not completely removed from the prescribing information.
Healthcare professionals were still advised to consider individual risk factors and monitor patients appropriately.
What Did Later Trials of Empagliflozin and Dapagliflozin Show?
The findings from CANVAS raised an important question:
Was the increased amputation risk specific to canagliflozin, or was it a problem with the entire SGLT2 inhibitor class?
Later clinical trials helped clarify the issue.
Clinical Trial Evidence Comparison
| Clinical Trial | Medicine | Amputation Finding | Practical Takeaway |
|---|---|---|---|
| CANVAS Program | Canagliflozin | Approximately twofold increased lower-limb amputation risk | Important safety signal requiring foot-risk assessment |
| EMPA-REG OUTCOME | Empagliflozin | No comparable increase established in reported analyses | CANVAS signal was not consistently reproduced |
| DECLARE-TIMI 58 | Dapagliflozin | No significant increase in amputation risk | No similar signal demonstrated in this trial |
| CREDENCE | Canagliflozin | No statistically significant increase in amputations | Later findings differed from CANVAS |
These studies included different patient populations and clinical protocols.
Therefore, trial findings should not be interpreted as proof that every SGLT2 inhibitor is completely free of foot-related risks.
Empagliflozin and Diabetic Foot Risk
Empagliflozin has demonstrated cardiovascular benefits in selected patients.
Available major trial evidence has not established the same increased amputation signal reported in CANVAS.
However, a patient taking empagliflozin can still develop diabetic foot ulcers because diabetes, neuropathy and peripheral artery disease remain independent risk factors.
Foot screening is therefore important regardless of the medication used.
Dapagliflozin and Foot Ulcers
Patients often ask about dapagliflozin and foot ulcer risk.
The DECLARE-TIMI 58 trial did not demonstrate a significant increase in lower-limb amputations with dapagliflozin.
This is reassuring, but it does not eliminate the need for individual assessment.
A patient with an active ulcer, severe infection or reduced blood supply should have both the foot condition and medication plan reviewed.
Why Did CREDENCE Show Different Results?
CREDENCE evaluated canagliflozin in patients with type 2 diabetes and chronic kidney disease.
Unlike CANVAS, it did not demonstrate a statistically significant increase in lower-limb amputation.
Trial populations, monitoring practices and treatment protocols differed.
The findings suggest that the original CANVAS signal should not automatically be generalized to every SGLT2 inhibitor or every patient.
Nevertheless, clinicians should continue to consider individual foot-risk factors.
Who Should Pause or Avoid an SGLT2 Inhibitor?
SGLT2 inhibitors can be beneficial medicines, but some situations require additional caution.
SGLT2 inhibitors amputation risk should be reviewed in the context of a patient's current foot health, circulation, hydration and overall medical condition.
Patients Who Need a Medication Review
A review is especially important for people with:
-
An active diabetic foot ulcer
-
Severe peripheral artery disease
-
Previous toe, foot or leg amputation
-
Recurrent diabetic foot infections
-
Significant dehydration
-
Acute illness with poor oral intake
-
Planned major surgery
-
Suspected diabetic ketoacidosis
An active ulcer does not automatically mean that every SGLT2 inhibitor must be stopped.
The decision depends on the specific medicine, severity of illness, local prescribing guidance and individual risk-benefit assessment.
Pause-and-Review Checklist
- Is there a new or worsening foot ulcer?
-
Is the foot red, swollen, infected or unusually cold?
-
Has the patient previously undergone amputation?
-
Is there known severe peripheral artery disease?
-
Is the patient vomiting, dehydrated or unable to eat normally?
-
Is surgery or prolonged fasting planned?
-
Has the treating physician reviewed kidney function and medication risks?
If any of these concerns apply, contact the treating physician promptly.
For patients with poor circulation, understanding peripheral artery disease is particularly important.
When Should SGLT2 Inhibitors Be Temporarily Withheld?
During acute illness, prolonged fasting, major surgery or suspected ketoacidosis, SGLT2 inhibitors may need to be temporarily withheld according to medical guidance.
These medicines can contribute to diabetic ketoacidosis, sometimes even when blood glucose is not markedly elevated.
Symptoms requiring urgent medical assessment include:
-
Nausea or vomiting
-
Abdominal pain
-
Rapid or deep breathing
-
Unusual fatigue
-
Confusion
-
Signs of dehydration
Patients should follow their prescribed sick-day plan and seek emergency care if ketoacidosis is suspected.
Medication decisions should be made with the treating physician.
Why Do These Drugs Still Matter for Heart and Kidney Protection?
Despite the historical amputation concern, SGLT2 inhibitors remain important medicines for many patients.
Clinical trials have demonstrated benefits in selected populations with type 2 diabetes, heart failure and chronic kidney disease.
Cardiovascular Benefits
Certain SGLT2 inhibitors reduce the risk of hospitalisation for heart failure.
Some have also demonstrated benefits for other cardiovascular outcomes in specific patient populations.
These effects are important because diabetes frequently coexists with cardiovascular disease.
Kidney Protection
SGLT2 inhibitors can slow chronic kidney disease progression in eligible patients.
This benefit may be particularly important for people with diabetes and reduced kidney function.
The medicine choice depends on kidney function, clinical indication and current prescribing recommendations.
Why Stopping Without Advice Can Be Harmful
Stopping a beneficial medicine without a replacement plan may worsen blood glucose control or interrupt heart and kidney protection.
For this reason, patients should not independently discontinue treatment simply because they have read about amputation risk.
Instead, they should request an endocrinologist opinion to review the medicine and their overall health.
A balanced decision considers both potential harms and established benefits.
How Are the Feet Monitored While on an SGLT2 Inhibitor?
Foot monitoring is important for people with diabetes, especially those with neuropathy, vascular disease or previous ulcers.
The goal is to identify problems before they become severe.
1. Daily Foot Inspection
Check both feet every day.
Look for:
-
Cuts or cracks
-
Blisters
-
Redness
-
Swelling
-
New wounds
-
Skin colour changes
-
Discharge
-
Unusual warmth
Patients with neuropathy may not feel pain even when a wound is serious.
2. Regular Sensation Testing
Diabetic neuropathy can reduce protective sensation.
Doctors may use a monofilament, tuning fork or other clinical tests to assess nerve function.
Reduced sensation increases the risk of unnoticed injury.
3. Circulation Assessment
Poor circulation can increase the risk of delayed healing and tissue loss.
A clinician may check foot pulses and recommend vascular investigations when indicated.
Patients with known vascular disease need appropriate follow-up.
4. Appropriate Footwear
Comfortable, protective footwear helps reduce repeated pressure and friction.
Patients with deformity, neuropathy or previous ulcers may need specialised footwear.
Walking barefoot should be avoided when protective sensation is reduced.
5. Early Specialist Review
Patients with previous ulceration or amputation may benefit from a structured high-risk foot programme.
Early assessment of a new wound can reduce delays in treatment.
Diabetes Medicine Review in Jamnagar: When Should Patients Seek Advice?
Patients who develop a foot ulcer while taking an SGLT2 inhibitor should request a clinical review rather than independently stopping medication.
The treating physician or endocrinologist can evaluate the medicine's benefits, kidney function, hydration and potential risks.
At Elegance Diabetic Foot & Ulcer Clinic (EDFC), Dr. Ashutosh Shah is associated with diabetic foot assessment, wound management and evaluation of complications such as reduced circulation and tissue damage. Medication changes should be directed by the patient's treating physician or endocrinologist, while foot-risk findings should inform that decision.
A review may be particularly important when a patient has:
-
A newly developed foot ulcer
-
A history of toe amputation
-
Recurrent infection
-
Severe peripheral artery disease
-
Dehydration or acute illness
-
Difficulty maintaining adequate food and fluid intake
Patients may also benefit from broader metabolic assessment through the metabolic health clinic.
What Should Patients Ask Their Doctor?
Before changing diabetes medication, consider discussing these questions:
-
Why was this particular SGLT2 inhibitor prescribed?
-
Am I taking it mainly for blood glucose, heart protection or kidney protection?
-
Does my current foot condition change the risk-benefit balance?
-
Do I need a circulation assessment?
-
What should I do during fever, vomiting or dehydration?
-
When should I temporarily stop the medicine before surgery?
-
What symptoms require urgent medical attention?
-
How often should my feet be examined?
These questions can support a more informed treatment decision.
Conclusion
SGLT2 inhibitors amputation risk became a major concern after the CANVAS Program identified increased lower-limb amputations among canagliflozin users.
However, later trials involving empagliflozin, dapagliflozin and canagliflozin did not consistently reproduce the same finding.
The FDA removed canagliflozin's boxed warning in 2020, while retaining information about the risk in prescribing guidance.
For many patients, SGLT2 inhibitors provide important heart and kidney benefits.
Patients with active diabetic foot ulcers, severe peripheral artery disease or previous amputation should have their foot health and medication plan reviewed together.
At Elegance Diabetic Foot & Ulcer Clinic, Dr. Ashutosh Shah is associated with specialist diabetic foot assessment and complication management.
The safest approach is coordinated care between the treating physician or endocrinologist and the diabetic foot specialist.
quiz Frequently Asked Questions
This article is general education, not a diagnosis. If you have a diabetic foot wound, please have it assessed in person. Send a photo on WhatsApp or book a consultation.
About the Author
Dr. Ashutosh Shah, Plastic, Reconstructive & Diabetic Foot Surgeon, Elegance Diabetic Foot & Ulcer Clinic, Surat
Dr. Ashutosh Shah is a board certified plastic and reconstructive surgeon with over 22 years of experience and more than 10,000 limbs and feet saved. He founded Elegance Diabetic Foot & Ulcer Clinic, India's first chain of clinics dedicated to foot care, with centres in Surat and OPD partners across South Gujarat. He is known for a limb first approach, safe wound care and ethical, natural results.
